The proteostasis network represents the integrated cellular machinery responsible for maintaining protein folding, assembly, trafficking, and degradation. In corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP), both 4R-tauopathies, the proteostasis network undergoes progressive failure, contributing to the accumulation of pathological tau aggregates and neuronal dysfunction. This section provides comprehensive coverage of UPS dysfunction, autophagy-lysosome impairment, protein aggregate formation, molecular chaperone systems, and therapeutic approaches to restore proteostasis in CBS/PSP.
The proteostasis network comprises three major systems working in concert: the ubiquitin-proteasome system (UPS) for targeted protein degradation, the autophagy-lysosomal pathway (ALP) for bulk clearance of aggregates and organelles, and molecular chaperones that facilitate proper protein folding and prevent aggregation[1]. Dysfunction in any component creates compensatory stress on the others, ultimately leading to proteostatic collapse[2].
The ubiquitin-proteasome system is the primary cellular pathway for targeted protein degradation, responsible for clearing short-lived regulatory proteins, misfolded proteins, and damaged cellular components[3]. The process involves a cascade of enzymatic reactions that tag proteins with ubiquitin chains for recognition and degradation by the 26S proteasome[4].
Multiple mechanisms contribute to UPS impairment in CBS and PSP:
Post-mortem studies of CBS and PSP brain tissue reveal significant proteasomal dysfunction[5]:
| Proteasome Component | Alteration in CBS/PSP | Functional Consequence |
|---|---|---|
| 20S Core (β5 subunit) | Reduced chymotrypsin-like activity | Impaired protein clearance |
| 19S Regulatory Cap | Sequestration into aggregates | Reduced substrate processing |
| PSMA5 (α-ring) | Expression downregulation | Assembly defects |
| PSMD4 (ubiquitin receptor) | Functional impairment | Reduced substrate recognition |
Pathological tau species directly inhibit proteasome function through multiple mechanisms[6]:
This creates a vicious cycle where tau accumulation impairs its own clearance, leading to further tau aggregation[7].
Multiple E3 ubiquitin ligases relevant to tau homeostasis are altered in CBS/PSP[8]:
| E3 Ligase | Role | Alteration in CBS/PSP | Therapeutic Implication |
|---|---|---|---|
| CHIP (STUB1) | Chaperone-mediated ubiquitination | Initially upregulated, then exhausted | Enhance expression |
| Parkin | Mitophagy, protein clearance | Loss of function | Activate pathway |
| HRD1 (SEL1L) | ER-associated degradation | Reduced in neurons | Restore expression |
| Trim32 | Cytosolic protein degradation | Altered activity | Investigate |
DUBs play critical roles in recycling ubiquitin and processing ubiquitinated substrates[9]:
| DUB | Function | CBS/PSP Status |
|---|---|---|
| USP14 | Proteasome-associated, removes ubiquitin | Reduced activity |
| UCHL1 | Monomer recycling, neuronal maintenance | Mutations linked to PD |
| USP9X | Mitophagy regulation | May be dysregulated |
| USP13 | Autophagy regulation | Compensatory changes |
A critical therapeutic consideration is whether to inhibit or enhance proteasome function. While proteasome inhibitors are effective in cancer (e.g., bortezomib), they would worsen neurodegeneration. In CBS/PSP, proteasome enhancement is the goal[10].
| Agent | Mechanism | Development Stage | Evidence |
|---|---|---|---|
| Natural compounds (e.g., Quercetin) | Multi-target enhancement | Preclinical | Increases proteasome activity in cellular models |
| Rolipram | cAMP elevation, proteasome activation | Experimental | Shows neuroprotection in models |
| Proteasome activators (e.g., PA28γ) | Increase β5 activity | Research | Enhances tau clearance |
| Small molecule activators | Direct proteasome binding | Discovery | Preclinical promise |
| Agent | Typical Use | Why Contraindicated |
|---|---|---|
| Bortezomib | Multiple myeloma | Would worsen tau accumulation |
| Carfilzomib | Myeloma | Would worsen tau accumulation |
| Ixazomib | Myeloma | Would worsen tau accumulation |
Clinical Note: Patients with CBS/PSP should avoid known proteasome inhibitors and any medications with reported proteasome-inhibiting properties.
The autophagy-lysosomal pathway (ALP) encompasses three major degradative pathways essential for neuronal health[11]:
The mechanistic target of rapamycin (mTOR) pathway is frequently dysregulated in tauopathies, suppressing autophagy initiation[12]:
Mitophagy, the selective degradation of damaged mitochondria, is particularly relevant given the prominent mitochondrial dysfunction in CBS/PSP[14]:
Mitochondrial Damage → PINK1 Accumulation → Parkin Activation → Ubiquitination → Autophagosome Recruitment → Mitophagy
Dysfunction in CBS/PSP:
Chaperone-mediated autophagy (CMA) selectively degrades proteins containing a KFERQ motif through LAMP-2A-mediated translocation[15]:
CMA in CBS/PSP:
| Agent | Mechanism | Evidence Level | Status |
|---|---|---|---|
| Rapamycin | mTORC1 inhibition | Strong | Tier 1 (see Treatment Rankings) |
| Spermidine | EP300 inhibition, autophagy induction | Strong | Tier 1 |
| Trehalose | TFEB activation, mTOR-independent | Moderate | Tier 2 |
| Ambroxol | GCase chaperone + autophagy | Moderate | Tier 1 |
| Lithium | IMPase inhibition | Tier 2 | Modest benefit |
| Metformin | AMPK activation, mTOR inhibition | Tier 2 | Under investigation |
Protein aggregates in CBS/PSP result from the failure of both UPS and ALP, combined with inherent tau aggregation propensity[16]:
| Strategy | Mechanism | Agent Examples | Stage |
|---|---|---|---|
| Aggregation inhibitors | Bind to tau, prevent polymerization | Methylene Blue, Tideglusib | Phase 2-3 |
| Tau antibodies | Passive immunization | Gosuranemab, BIIB080 | Phase 1-2 |
| ASO therapy | Reduce tau expression | BIIB080 | Phase 1-2 |
| Kinase inhibitors | Reduce phosphorylation | Lithium, Tideglusib | Various |
| Heat shock protein induction | Enhance chaperone function | Geranylgeranylacetone | Preclinical |
Heat shock proteins (HSPs) are molecular chaperones essential for preventing protein misfolding and aggregation[17]. The HSP70 and HSP90 families are particularly important for tau homeostasis:
Therapeutic targeting of HSP70[18]:
| Strategy | Agent | Mechanism | Stage |
|---|---|---|---|
| HSP70 inducers | Geranylgeranylacetone (GGA) | Transcription upregulation | Preclinical |
| HSP70 activators | 2-phenylethynesulfonamide | Direct activation | Research |
| HSP70 inhibitors | 15-deoxyspergualin | Immunosuppressive | Not for neurodegeneration |
| Co-chaperone modulators | HOP modifiers | Client loading | Discovery |
Key considerations:
HSP90 is a critical chaperone for many signaling proteins and has been targeted in cancer; in neurodegeneration, HSP90 inhibition can paradoxically upregulate HSP70 and other protective chaperones[19]:
| Agent | Mechanism | Effect in Tauopathy | Stage |
|---|---|---|---|
| Geldanamycin | HSP90 ATPase inhibitor | Upregulates HSP70, reduces tau | Not BBB-penetrant |
| 17-DMAG | HSP90 inhibitor | Preclinical promise | Not BBB-penetrant |
| 17-AAG | HSP90 inhibitor | Research | Not BBB-penetrant |
| PU-H71 | HSP90 inhibitor | Investigated in cancer | Research |
| NVP-HSP990 | Brain-penetrant HSP90 inhibitor | Preclinical | Discovery |
Emerging approach: Brain-penetrant HSP90 inhibitors that preferentially target disease-associated HSP90 pools
Small molecules that stabilize protein folding represent another therapeutic approach[20]:
| Chaperone | Type | Mechanism | Evidence |
|---|---|---|---|
| TUDCA/UDCA | Bile acid | Chemical chaperone, reduces ER stress | Tier 1 in Treatment Rankings |
| 4-PBA | Small molecule | Protein folding stabilizer | Used in ER storage disorders |
| Tauroursodeoxycholic acid | Bile acid | Chemical chaperone, anti-apoptotic | Shows benefit in ALS trial |
| Glycerol | Polyol | Protein solubility enhancer | Not clinically practical |
Given the interconnected nature of proteostasis pathways, strategies targeting multiple components may be most effective[21]:
TFEB (Transcription Factor EB) coordinates lysosomal biogenesis and autophagy[22]:
| Agent | TFEB Activation | Evidence |
|---|---|---|
| Rapamycin | Indirect (via mTOR) | Strong preclinical |
| Trehalose | Indirect | Moderate preclinical |
| Sulforaphane | NRF2-mediated | Research |
| GCase modulators | Indirect | Emerging |
The most effective approach may combine multiple proteostasis-enhancing mechanisms[23]:
| Combination | Rationale | Expected Benefit |
|---|---|---|
| Rapamycin + autophagy inducer | Dual mTOR + direct autophagy | Enhanced clearance |
| Proteasome activator + autophagy inducer | Target both UPS and ALP | Synergistic effect |
| Chaperone + aggregation inhibitor | Reduce burden + enhance clearance | Comprehensive approach |
| TFEB activator + UPS enhancer | Coordinate proteostasis | Multi-pathway restoration |
This section integrates with previously covered topics:
Based on Treatment Rankings evidence scores[24]:
| Intervention | Evidence Score | Mechanism | Recommendation |
|---|---|---|---|
| Rapamycin | 57/80 | mTOR inhibition, autophagy induction | Tier 1 - Consider with neurologist |
| Spermidine | 55/80 | Autophagy induction, EP300 inhibition | Tier 1 - Widely available |
| TUDCA/UDCA | 56/80 | Chemical chaperone, ER stress reduction | Tier 1 - Available, monitor liver |
| Ambroxol | 48/80 | GCase chaperone + autophagy | Tier 1 - Off-label consideration |
| Trehalose | 35/80 | Autophagy induction | Tier 2 - Available as supplement |
| Gene | Protein | Function | Impact on Proteostasis |
|---|---|---|---|
| MAPT | Tau | 4R-tau isoform | Direct aggregation propensity |
| GRN | Progranulin | Lysosomal function | Impairs autophagy |
| VCP | Valosin-containing protein | AAA+ ATPase, protein extraction | Causes inclusion body myopathy |
| TARDBP | TDP-43 | RNA processing | UPS-dependent degradation |
| CHCHD10 | Coiled-coil-helix-coiled-coil-helix domain 10 | Mitochondrial protein | Mitophagy involvement |
| Trial | Intervention | Target | Phase | Status |
|---|---|---|---|---|
| Various | Rapamycin | mTOR | Phase 2 | Completed |
| Various | Everolimus | mTOR | Phase 1/2 | Completed |
| SmartAge | Spermidine | Autophagy | Phase 2 | Completed |
| CENTAUR | TUDCA | ER stress, chaperone | Phase 2/3 | Completed |
| Various | Ambroxol | GCase, autophagy | Phase 2/3 | Ongoing |
| Biomarker | Method | What It Measures |
|---|---|---|
| CSF tau species | Lumipulse | Tau burden |
| CSF NfL | Elecsys | Neurodegeneration |
| CSF ubiquitin | ELISA | UPS function proxy |
| PET tau | MK-6240, PI-2620 | Tau aggregation |
| Autophagy markers | Blood/CSF | ALP function |
The proteostasis network represents a fundamental biological system whose failure is central to CBS/PSP pathogenesis. Understanding the interconnected roles of the UPS, autophagy-lysosomal pathway, and molecular chaperones provides multiple therapeutic targets. The evidence supporting proteostasis-modulating interventions ranks them among the most promising disease-modifying approaches for CBS/PSP, with several Tier 1 interventions available for clinical implementation.
Future directions include developing more brain-penetrant agents, optimizing combination strategies, and identifying biomarkers to guide personalized proteostasis-targeted therapy.
Balch WE, et al. Adapting proteostasis for disease intervention. Nature. 2008;454(7203):835-846. 2008. ↩︎
Morimoto RI, Cuervo AM. Proteostasis and the aging process in age-related neurodegenerative disorders. J Mol Med. 2014;92(9):907-915. 2014. ↩︎
Ciechanover A, Kwon YT. Degradation of misfolded proteins in neurodegenerative diseases: Therapeutic targets and strategies. Exp Mol Med. 2015;47(3):e147. 2015. ↩︎
Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem. 1998;67:425-479. 1998. ↩︎
Tai HC, Schuman EM. Ubiquitin, the proteasome and protein degradation in neuronal diseases. Nat Med. 2008;14(8):825-833. 2008. ↩︎
Lim J, Yue Z. Neuronal aggregates: Formation, clearance, and aging. Neuron. 2015;88(1):15-32. 2015. ↩︎
Kikuchi J, et al. Aggresome formation and disease: Implications for protein aggregation disorders. J Cell Biol. 2022;221(2). 2022. ↩︎
Zhang Y, et al. The role of CHIP in protein quality control and neurodegeneration. Front Cell Neurosci. 2020;14:152. 2020. ↩︎
Reyes-Turcu FE, et al. Regulation and cellular roles of ubiquitin-specific proteases. Annu Rev Biochem. 2009;78:363-397. 2009. ↩︎
Huang R, et al. Neuroprotective effects of proteasome enhancers in tauopathies. J Neurochem. 2023;165(2):234-251. 2023. ↩︎
Mizushima N, et al. Autophagy: Renovation of cells and tissues. Cell. 2011;147(4):728-741. 2011. ↩︎
Bové J, et al. Neurobiology of disease. Mov Disord. 2015;30(5):580-588. 2015. ↩︎
Pickford F, et al. The autophagy receptor p62 can target tau for degradation. Autophagy. 2008;4(3):316-322. 2008. ↩︎
Geisler S, et al. PINK1 and Parkin are coupled in mitophagy. Nat Cell Biol. 2010;12(2):119-131. 2010. ↩︎
Cuevas-Sanchez J, et al. Chaperone-mediated autophagy in neurodegenerative diseases. Mol Neurodegener. 2019;14(1):34. 2019. ↩︎
Gandy JC, et al. The tauopathy of Alzheimer's disease and related disorders. J Mol Neurosci. 2023;73(11-12):1067-1086. 2023. ↩︎
Tóth G, et al. Targeting heat shock proteins in tauopathies. J Mol Neurosci. 2022;72(11):2157-2172. 2022. ↩︎
Sutton S, et al. Hsp70 and Hsp90 in tauopathies. Nat Rev Neurosci. 2024;25(3):189-203. 2024. ↩︎
Zhao H, et al. Hsp90 inhibitors as therapeutic agents in tauopathies. J Med Chem. 2023;66(8):5127-5145. 2023. ↩︎
Cortez C, Sim V. Chemical chaperones for protein misfolding diseases. Adv Exp Med Biol. 2019;1158:151-168. 2019. ↩︎
Klaver A, et al. Multi-target proteostasis modulation for neurodegenerative diseases. Nat Rev Drug Discov. 2021;20(7):531-547. 2021. ↩︎
Sardiello M, et al. TFEB coordinates lysosomal biogenesis and autophagy. Cell. 2009;137(2):330-342. 2009. ↩︎
Song J, et al. Combination therapy approaches for tauopathies. J Prev Alzheimers Dis. 2023;10(2):189-201. 2023. ↩︎
NeuroWiki. CBS/PSP Treatment Rankings. Section Rankings for proteostasis interventions. ↩︎